Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

1598303

USP

Ramipril

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Tritace, [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H32N2O5
Número de CAS:
87333-19-5
Peso molecular:
416.51
MDL number:
MFCD00865775
UNSPSC Code:
41116107
PubChem Substance ID:
329751020
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ramipril

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C(N1[C@](CCC2)([H])[C@]2([H])C[C@H]1C(O)=O)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3

InChI

1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

InChI key

HDACQVRGBOVJII-JBDAPHQKSA-N

Gene Information

human ... ACE(1636)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

1598314

Ramipril Related Compound A, United States Pharmacopeia (USP) Reference Standard

1598347

Ramipril Related Compound D, United States Pharmacopeia (USP) Reference Standard

R0145000

Ramipril, European Pharmacopoeia (EP) Reference Standard

R0145005

Ramipril impurity A, European Pharmacopoeia (EP) Reference Standard

R0145020

Ramipril impurity D, European Pharmacopoeia (EP) Reference Standard

R0145010

Ramipril impurity B, European Pharmacopoeia (EP) Reference Standard

R0145015

Ramipril impurity C, European Pharmacopoeia (EP) Reference Standard

1598323

Ramipril Related Compound B, United States Pharmacopeia (USP) Reference Standard

1598338

Ramipril Related Compound C, United States Pharmacopeia (USP) Reference Standard

BP751

Ramipril, British Pharmacopoeia (BP) Reference Standard

BP754

Ramipril impurity K, British Pharmacopoeia (BP) Reference Standard

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360FD

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Carolina De Ciuceis et al.
Hypertension (Dallas, Tex. : 1979), 64(4), 717-724 (2014-07-02)
Structural alterations of subcutaneous small-resistance arteries are associated with a worse clinical prognosis in hypertension and non-insulin-dependent diabetes mellitus. The effects of the direct renin inhibitor aliskiren on microvascular structure were never previously evaluated. Therefore, we investigated the effects of
April D Vuong et al.
The Annals of pharmacotherapy, 37(3), 412-419 (2003-03-18)
To evaluate the effectiveness of ramipril in the prevention and treatment of cardiovascular disease and determine its need for inclusion on a formulary. A MEDLINE and PubMed database search was conducted (1987-May 2002). Only journals written in the English language
J E Frampton et al.
Drugs, 49(3), 440-466 (1995-03-01)
Ramipril is a second generation angiotensin converting enzyme (ACE) inhibitor. Like enalapril, it is a prodrug and is hydrolysed in vivo to release the active metabolite, ramiprilat, which has a long elimination half-life, permitting once-daily administration. The antihypertensive efficacy of
W Linz et al.
Zeitschrift fur Kardiologie, 83 Suppl 4, 53-56 (1994-01-01)
ACE inhibitors induce an increase in kinin levels with subsequent release of nitric oxide (NO) and prostacyclin, as shown in cultured endothelial cells and isolated rat hearts. Isolated perfused working rat hearts continuously release kinins and prostacyclin. During ischemia after
Antonios Douros et al.
American journal of hypertension, 26(9), 1070-1075 (2013-06-12)
Ramipril, an inhibitor of the angiotensin-converting enzyme (ACEI), is a drug commonly used in the therapy of hypertension. ACEI-induced hepatotoxicity is rare, and most of the reported cases are associated with captopril. Here, we present the first case of ramipril-induced
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico